Peramivir (trihydrate)

Peramivir (trihydrate)

• CAS Number: 1041434-82-5
• UNSPSC Description: Peramivir trihydrate (RWJ-270201 trihydrate) is a highly potent, selective and orally active influenza virus neuraminidase (NA) inhibitor, with IC50 values ranging from 0.9 to 4.3 nM for nine NA subtypes[1][2][3].
• Target Antigen: ERK; IKK; Influenza Virus; JNK; p38 MAPK; STAT
• Type: Reference compound
• Related Pathways: Anti-infection;JAK/STAT Signaling;MAPK/ERK Pathway;NF-κB;Stem Cell/Wnt
• Applications: COVID-19-anti-virus
• Field of Research: Infection; Inflammation/Immunology
• Assay Protocol: https://www.medchemexpress.com/Peramivir-trihydrate.html
• Solubility: DMSO : < 1 mg/mL (ultrasonic)|H2O : 5 mg/mL (ultrasonic)
• Smiles: O[C@H]1[C@]([C@H](C(CC)CC)NC(C)=O)([H])[C@H](NC(N)=N)C[C@@H]1C(O)=O.[H]O.[H]O.[H]O
• Molecular Weight: 382.45
• References & Citations: [1]Zhang C, et al. Peramivir, an anti-influenza virus drug, exhibits potential anti-cytokine storm effects [J]. Frontiers in Immunology, 2022, 13: 856327.|[2]Pascua P N Q, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection [J]. Scientific reports, 2017, 7(1): 7345.|[3]Alame M M, et al.. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections [J]. Frontiers in microbiology, 2016, 7: 450.Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00222-20.|PLoS One. 2018 Jul 12;13(7):e0200761. |Chemosphere. 2017 Feb;169:550-557.|Int Immunopharmacol. 2023 Jan 11;115:109706.|Int J Infect Dis. 2024 Jun 27:107134.|Nat Commun. 2013;4:2854.|PLoS One. 2015 Jun 25;10(6):e0131412.|PLoS Pathog. 2024 Feb 14;20(2):e1011981.|Sci Rep. 2021 Aug 11;11(1):16293.|University of Glasgow. School of Cancer Sciences.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched